Adding oxaliplatin to fluorouracil-based preoperative chemoradiotherapy significantly increases toxicity without affecting primary tumor response. Longer follow-up is needed to assess the impact on efficacy end points.
Role of the Funder/Sponsor: CDC staff had a role in the design and conduct of the project and collection and management of data in this project as part of the funding support and technical assistance given to state central cancer registries that participate in NPCR. The analysis and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication was the sole responsibility of the authors.
Disclaimer:The findings and conclusions are those of the authors and do not necessarily represent the official position of their affiliations or the CDC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.